Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user is experiencing rapid hair loss and has been diagnosed with telogen effluvium by multiple dermatologists, but doubts the diagnosis due to the severity and speed of the hair loss. They are considering various treatments like spironolactone, estradiol, and possibly finasteride, while also exploring the possibility of hormonal imbalances or autoimmune issues.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

Finasteride is available in Turkey without a prescription, with 1mg tablets costing 800 Turkish lira and 5mg tablets costing 150 lira. Oral minoxidil capsules were found at Cerrahpaşa nur eczanesi, also without a prescription.

Finasteride stopped working for a user after 3 years, and they are considering switching to dutasteride. Other users suggest trying dutasteride, with some sharing positive experiences and additional treatments like minoxidil and RU58841.

Dutasteride significantly reduces scalp DHT levels and can save hair, though shedding is part of the process. Some users report success with dutasteride, while others struggle despite using it along with finasteride and oral minoxidil.

Finasteride is the most effective treatment for reducing DHT and addressing hair loss compared to fish oil and saw palmetto. Topical treatments like RU58841 and minoxidil are also discussed, but finasteride remains the most effective option.

Creatine's impact on hair loss is debated, with some users reporting worsened hair loss and others seeing no effect. The consensus is that creatine does not significantly increase DHT or cause hair loss, but those already experiencing hair loss might be more affected.

The conversation discusses the effectiveness of a multivitamin containing Zinc, Biotin, B12, B6, B2, B1, Vitamin D, and Iron for hair loss. The multivitamin is from a reliable but inexpensive brand in Brazil.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Sugary beverages increase the risk of pattern hair loss in men by 57%, and type 2 diabetes is linked to female pattern hair loss. Reducing sugar intake and using treatments like finasteride and minoxidil may help manage hair loss.

The conversation discusses the effectiveness of hair loss treatments, specifically finasteride and dutasteride. The conclusion is that dutasteride significantly reduces DHT levels and may be more effective than finasteride for long-term hair retention, with some users reporting personal experiences and side effects.

A 27-year-old male physician improved hair density using minoxidil 5% foam and finasteride 1mg every other day, with initial sexual side effects that subsided. He recommends trying finasteride for a year but warns against dutasteride due to potential liver effects.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.